Systematic Review Confirms AVISE Lupus Superiority, Bolstering Exagen's Market Position
XGN sits 99% above its 52-week low of $2.59.
Summary
Exagen announced the publication of a systematic review validating the robust real-world performance of its AVISE Lupus diagnostic test. The review found AVISE Lupus uniquely identified 25% of SLE patients missed by conventional markers and demonstrated superior diagnostic accuracy. This positive product validation follows recent strong Q1 2026 revenue results, where Exagen exceeded estimates. The company's CEO highlighted that this reinforces their competitive moat, supports their premium market position, reimbursement strategy, and broader adoption, which is significant for a small-cap diagnostics company.
At the time of this announcement, XGN was trading at $5.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.3M. The 52-week trading range was $2.59 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.